Tuesday, November 29, 2022
Nov. 29, 2022

Linkedin Pinterest

CytoDyn begins testing COVID-19 treatment

The Columbian
Published:

Vancouver-based biotechnology company CytoDyn announced Thursday that it received authorization from the U.S. Food and Drug Administration to begin testing medication on two COVID-19 patients.

CytoDyn’s signature product, leronlimab, is an antibody originally developed to combat HIV infections, but CytoDyn is theorizing that it could also function as an anti-inflammatory agent that would prevent patients from developing Acute Respiratory Distress Syndrome, one of the potentially lethal complications that can arise from COVID-19 infections.

The two patients have begun to receive leronlimab treatment at a medical center in the New York City area, according to a press release from CytoDyn. The company described the two patients as among the most severe COVID-19 cases at the facility. Neither patient has had any serious adverse reactions to the medication thus far, the company said.

Support local journalism

Your tax-deductible donation to The Columbian’s Community Funded Journalism program will contribute to better local reporting on key issues, including homelessness, housing, transportation and the environment. Reporters will focus on narrative, investigative and data-driven storytelling.

Local journalism needs your help. It’s an essential part of a healthy community and a healthy democracy.

Community Funded Journalism logo
Loading...